New drug shows promise for rare stomach cancer in chinese patients
NCT ID NCT05381753
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how safe and effective the drug avapritinib is for Chinese patients with a rare type of stomach cancer called gastrointestinal stromal tumor (GIST). Researchers observed 61 patients in real-world clinics, not in a controlled lab setting. The goal was to track side effects and how well the drug worked for different patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Brain-Cancer drug take on a stubborn stomach tumor?
- Study aims to pinpoint ideal imatinib dose for GIST patients
- New hope for stubborn GIST: experimental drug DCC-2618 enters safety testing
- New drug cocktail targets tough stomach cancer in Last-Resort patients
- New hope for rare stomach cancer: chemo drug shows promise in early trial
- New oral paclitaxel trial offers hope for Hard-to-Treat GIST